Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Gross Margin: 2009-2025

Historic Gross Margin for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to 88.49%.

  • Amicus Therapeutics' Gross Margin fell 213.00% to 88.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 89.77%, marking a year-over-year decrease of 21.00%. This contributed to the annual value of 89.98% for FY2024, which is 67.00% down from last year.
  • Per Amicus Therapeutics' latest filing, its Gross Margin stood at 88.49% for Q3 2025, which was down 1.86% from 90.16% recorded in Q2 2025.
  • Amicus Therapeutics' Gross Margin's 5-year high stood at 91.95% during Q1 2023, with a 5-year trough of 83.55% in Q3 2022.
  • Over the past 3 years, Amicus Therapeutics' median Gross Margin value was 90.36% (recorded in 2023), while the average stood at 90.15%.
  • Per our database at Business Quant, Amicus Therapeutics' Gross Margin skyrocketed by 684bps in 2023 and then slumped by 424bps in 2024.
  • Over the past 5 years, Amicus Therapeutics' Gross Margin (Quarterly) stood at 90.44% in 2021, then plummeted by 110bps to 89.35% in 2022, then surged by 81bps to 90.16% in 2023, then dropped by 7bps to 90.09% in 2024, then slumped by 213bps to 88.49% in 2025.
  • Its Gross Margin was 88.49% in Q3 2025, compared to 90.16% in Q2 2025 and 90.66% in Q1 2025.